| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Pulmonary surfactant-associated protein D, PSP-D, SP-D, Collectin-7, Lung surfactant protein D, SFTPD, COLEC7, PSPD, SFTP4 |
| Entrez GeneID | 6441 |
| WB Predicted band size | 37.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This SFTPD antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 301-330 amino acids from the C-terminal region of human SFTPD. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SFTPD抗体的3篇参考文献，涵盖其功能、检测应用及疾病关联：
1. **"Surfactant Protein D in Innate Immunity: A Structural and Functional Perspective"**
- **作者**: Kishore U, Reid KBM
- **摘要**: 本文综述了SFTPD在先天免疫中的作用，重点讨论其通过凝集素结构域识别病原体的机制。研究提到利用特异性抗体阻断SFTPD与病原体的相互作用，验证其在免疫调节中的关键功能。
2. **"Genetic Variation in Surfactant Protein-D Modulates Lung Disease Risk"**
- **作者**: Sorensen GL, Hjelmborg JVB
- **摘要**: 通过人群队列分析，研究发现SFTPD基因多态性与COPD易感性相关。采用ELISA和单克隆抗体检测SFTPD血浆水平，揭示低水平SFTPD与肺部炎症加重的关联。
3. **"Autoantibodies Targeting Surfactant Protein D in Systemic Lupus Erythematosus"**
- **作者**: Ohnishi K, et al.
- **摘要**: 首次报道系统性红斑狼疮(SLE)患者血清中存在抗SFTPD自身抗体。通过免疫印迹法证实此类抗体与疾病活动性正相关，提示其可能参与肺部并发症的发生机制。
4. **"Surfactant Protein D as a Biomarker in Viral Pneumonia"**
- **作者**: Leth-Larsen R, et al.
- **摘要**: 研究评估SFTPD作为病毒性肺炎预后标志物的潜力，使用多克隆抗体进行支气管肺泡灌洗液检测，发现SFTPD水平与患者氧合指数改善显著相关。
以上文献涵盖了SFTPD抗体的功能研究、检测技术及临床疾病关联，均为该领域代表性成果。
The surfactant protein D (SFTPD) antibody is a reagent targeting SFTPD, a key component of the pulmonary surfactant system primarily produced by alveolar type II cells and airway epithelial cells. SFTPD belongs to the collectin family, playing a critical role in innate immunity by binding to pathogens, allergens, and apoptotic cells via its carbohydrate-recognition domain, facilitating their opsonization and clearance. It also modulates inflammatory responses, maintaining immune homeostasis in the lungs.
SFTPD antibodies are widely used in research to detect SFTPD expression in conditions like acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and viral infections (e.g., COVID-19). Altered SFTPD levels correlate with disease severity, making it a potential biomarker. Additionally, autoantibodies against SFTPD have been implicated in autoimmune disorders, such as rheumatoid arthritis and hypersensitivity pneumonitis, where aberrant immune responses target pulmonary tissues.
Clinically, SFTPD antibodies aid in diagnostic assays and therapeutic development. Neutralizing antibodies or recombinant SFTPD are explored for modulating immune dysregulation. However, elevated anti-SFTPD autoantibodies may exacerbate tissue damage, highlighting dual roles in protection and pathology. Understanding SFTPD-antibody interactions offers insights into lung disease mechanisms and therapeutic opportunities.
(Word count: 199)
×
